일동홀딩스
000230KOSPI의약품 제조업57.3 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
Iljung Holdings operates seven business divisions, including pharmaceuticals, advertising, ion water generators, software and medical devices, functional foods, and clinical pharmacology consulting. The company's main revenue comes from pharmaceutical manufacturing and sales (614.94 billion won) and software/medical device development (27.99 billion won), while advertising and ion water generator segments experienced declines compared to the previous year.
Number of Employees
84people
Average Salary
62.3M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
Half of industry avg (excellent)
1.8x industry avg (good)
3.3x industry avg (risky)
Avg ▼3.6% (2-year basis)
Avg ▲407.9% (2-year basis)
Avg ROE -12.2% (improving, 3yr)
Detailed News Sentiment
- Positive일동홀딩스, 1분기 영업익 88억원…전년비 117.5% 증가
일동홀딩스의 1분기 영업이익이 전년 대비 크게 증가하며 흑자 전환을 달성했다.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -24.25% (strong drop)
Volume decreasing
Detailed Disclosure
- Neutral기업지배구조보고서공시2026-05-29
- Neutral주식등의대량보유상황보고서(일반)2026-05-21
- Neutral분기보고서 (2026.03)2026-05-15
- Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-05-13
